Posts

Sanofi's Tolebrutinib Receives EMA Backing for Nonrelapsing Progressive MS Despite FDA Rejection

on

Roche's Fenebrutinib Delays MS Relapses in Phase 3 Trials but Faces Liver Toxicity and Safety Scrutiny

on

Immunic Appoints Jon Congleton to Board of Directors

on

Sanofi's Tolebrutinib Faces Phase 3 Failure in PPMS and FDA Delays in nrSPMS

on

Sanofi calls FDA rejection of potential MS blockbuster tolebrutinib “unexpected” amid evolving agency views on benefit–risk

on

ScinoPharm Taiwan Secures Historic U.S. FDA Approval for Glatiramer Acetate Injection to Treat Multiple Sclerosis

on

Sanofi’s multiple sclerosis drug tolebrutinib flunks Phase 3 in PPMS and faces another FDA PDUFA delay

on

Sandoz Launches Tyruko (Natalizumab-Sztn), First Tysabri Biosimilar, in US After JCV Assay Delays

on

Zenas BioPharma Inks $2 Billion+ Licensing Deal With InnoCare for Autoimmune Drug Candidates

on

FDA Delays Decision on Sanofi's Oral Multiple Sclerosis Drug to December 2025

on

Sanofi's MS Drug Tolebrutinib Faces FDA Delay Amid Extended Review

on

Immunic's MS drug shows 'modest' brain volume impact, stock tumbles

on